A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer. The findings, from an international clinical trial, reinforce earlier findings of the benefits of the drug — trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate — in these patients, trial leaders say.
You May Also Like
New temperatures in two thirds of key tropical forest
16 de outubro de 2024
Seven new frog species discovered in Madagascar: Sounds like something from Star Trek
16 de outubro de 2024
New test improves diagnosis of allergies
16 de outubro de 2024